TerminatedPhase 3NCT05329545
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mersana Therapeutics
- Principal Investigator
- Robert Burger, MD, M.DMersana Therapeutics
- Intervention
- Upifitimab rilsodotin(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2023
Study locations (30)
- HonorHealth Research Institute - HonorHealth VGPCC Biltmore, Phoenix, Arizona, United States
- The University of Arizona Cancer Center, Tucson, Arizona, United States
- University of California Los Angeles, Gynecologic Oncology Clinic, Los Angeles, California, United States
- University of California, Irvine Medical Center, Orange, California, United States
- Sarasota Memorial Hospital, Sarasota, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- WK Physicians, Shreveport, Louisiana, United States
- Karmanos Cancer Institute - Detroit, Detroit, Michigan, United States
- Billings Clinic, Billings, Montana, United States
- Methodist Hospital, Omaha, Nebraska, United States
- Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
- Center of Hope, Reno, Nevada, United States
- University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
- Southwest Women's Oncology, Albuquerque, New Mexico, United States
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
GOG Foundation · European Network of Gynaecological Oncological Trial Groups (ENGOT)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05329545 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd